Revidia Therapeutics expands leadership team
Revidia Therapeutics has expanded its leadership team to prepare for an FDA IND application and clinical trials. The company's lead drug candidate, MSI-1436, is being developed as a treatment for heart injury in Duchenne muscular dystrophy patients.